MSB 1.56% 97.5¢ mesoblast limited

Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19, page-216

  1. 433 Posts.
    lightbulb Created with Sketch. 44
    I don't think anyone is arguing with differences of opinion but it more around analysis or reasoning of sell recommendations is in question. As it was a lazy analysis with no real analysis or research is in question here
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.